Growth factors have been extensively researched in cancers, including bladder cancer, because of their role in cancer biology and clinical relevance as prognostic and therapeutic targets, and EGFR is a well-characterized initiator of the RAS signaling pathway upon activation by EGF (30). This evidence concerns the gene EGFR and cancer.